RxDoctor Payments Data

Irma Rasmussen, MD

Internal Medicine · Framingham, MANPI 1144287236

Payments from drug & device makers

$2,976in general payments, 2019–2025

Across 135 payments — averaging $22.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$576
  • Novo Nordisk$557
  • Pfizer$539
  • Lilly USA, LLC$203
  • Boehringer Ingelheim$158
  • Shield Therapeutics Inc$103
  • plus $840 from 22 others

What the payments were for

  • Food & beverage$2,976100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,976 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$95,028
Medicare patients
241
Services billed
1,064

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin123$98,290
EliquisApixaban59$50,091
TrulicityDulaglutide40$42,669
MounjaroTirzepatide19$27,586
JanuviaSitagliptin Phosphate32$27,236
FarxigaDapagliflozin Propanediol37$26,634
OzempicSemaglutide16$23,541
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$17,846
RybelsusSemaglutide13$12,259
XareltoRivaroxaban18$9,329
Atorvastatin Calcium710$8,163
Combivent RespimatIpratropium/Albuterol Sulfate14$6,444
Incruse ElliptaUmeclidinium Bromide16$5,839
Rosuvastatin Calcium135$4,305
Metoprolol Succinate218$3,923

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$158$104,734137 claims
Lilly USA, LLCTrulicity, Mounjaro$203$70,25559 claims
PfizerEliquis, Prempro$539$53,00271 claims
Novo NordiskOzempic, Rybelsus$557$35,80029 claims
MerckJanuvia$16$27,23632 claims
AstraZenecaFarxiga$576$26,63437 claims
GSKTrelegy Ellipta, Incruse Ellipta$71$23,68535 claims
Johnson & JohnsonXarelto$80$9,32918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Framingham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →